Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.
Mount Sinai bioinformaticians have quickly pivoted from Lyme disease research to building a reference tool for researchers pursuing COVID therapies.
The Medicare Administrative Contractor's decision covers molecular diagnostic laboratory tests as predictive classifiers for non-small cell lung cancer.
Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.
Researchers argued that the field is ready for an expansion of adjuvant therapy trials informed by non-invasive, molecular measures of minimal residual disease.
Using protein interaction experiments, researchers identified agents that could disrupt SARS-CoV-2 and human proteins that bind to each other.
Using single-cell RNA sequencing, researchers identified cells in mouse and human prostate tissues that appear to help regrow the gland after prostate cancer treatment.
The drugmaker will promote Zejula without a biomarker as a first-line maintenance option, and Myriad will highlight that patients with HRD are most likely to benefit.
In Nature this week: combining genome-wide association and transcriptome study data homes in on cells involved in brain disorders, and more.
The kit uses components that are chemically identical to ones in the SARS-CoV-2 test kit that the company offers in the US under an Emergency Use Authorization.
The funding will support the firm's international market expansion on the heels of the release of Lifebit CloudOS version 2.0 this week.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The company said it intends to use the proceeds for general corporate purposes and to repay borrowings under its term loan facility.
The endpoint RT-PCR test is processed on the company's Encompass CARD cartridge, which runs on Rheonix's Encompass MDx workstation.
Under the deal, the companies aim to develop a companion diagnostic for Bayer's solid tumor drug larotrectinib for the Chinese market.
The test is a modified version of Thermo Fisher Scientific's TaqPath COVID-19 SARS-CoV-2 Test, which received Emergency Use Authorization last month.
Customer site shutdowns, particularly in the last several weeks of the quarter, negatively impacted sales by about 3 percent, the firm said.
Timothy Chan has been appointed director of the Center for Immunotherapy and Precision Immuno-oncology at Cleveland Clinic. Chan joins the clinic from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he chaired the immunogenomics and precision oncology platform and was a tenured professor. He also was chair of the translational oncology division. Chan also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University; and is on staff at the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute. He holds an MD and PhD in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and postdoc in tumor biology.